HEPI Pharmaceuticals

HEPI Pharmaceuticals was a private biotechnology company based in Alameda, California, that specialized in the development of immunotherapies for chronic viral infections. The company's lead product candidate was HepX, a synthetic peptide designed to act as a host-response modifier for patients with chronic Hepatitis C. HepX was intended to stimulate the patient's own immune system to recognize and eliminate the virus, providing a potentially safer alternative to the interferon-based regimens standard at the time. The company successfully advanced HepX into Phase 2 clinical trials, demonstrating its commitment to addressing significant unmet needs in hepatology. Despite its clinical progress, HEPI Pharmaceuticals ceased operations in the mid-2000s as the therapeutic landscape for Hepatitis C evolved toward more effective direct-acting antiviral agents.